Loading
Life sciences · Journal article
Siberian Journal of Oncology · September 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Objective: to summarize current trends in the use of abiraterone in the treatment of prostate cancer based on clinical and experimental studies. Material and Methods. We searched and analyzed information in MedLine, Scopus, WoS, and the Russian Science Citation Index (RSCI) databases for the past 10 years. We analyzed information on pharmaceutical, experimental, and clinical studies on current trends in abiraterone use strategies for prostate cancer treatment, based on clinical and experimental studies. Results. Abiraterone-based therapies are being actively studied for the treatment of both hormone-sensitive and castration-resistant prostate cancer. The use of abiraterone-based therapies or irreversible androgen receptor blockers leads to long-term disease control and improved treatment outcomes for prostate cancer patients. Regulation of testosterone levels between castration and supraphysiological levels suppresses the growth of cancer cells (bipolar androgen therapy). Significant limitations in the use of abiraterone-based therapies are associated with their side effects: changes in water-electrolyte balance due to the effect on the level of mineralocorticoids in the blood, and the development of relative or absolute liver and kidney failure. To reduce the dose and/or increase the bioavailability of the drug, two main approaches are used: using the positive effect of food to increase exposure and the development of supergenerics. Current strategies for overcoming resistance to deprivation and chemotherapy include combination therapy using agents with different mechanisms of pharmacological activity, metronomic administration, and the development of new modified antitumor agents that combine a cytotoxic and antiandrogenic component in a single molecule. Pharmacologically active compounds, such as abiraterone, have been developed using organotin compounds, offering dual (multimodal) action and actively inducing apoptosis and inhibiting proliferation in the G2/M phase of the cell cycle (in vitro studies). Conclusion. The combination of these approaches has the potential to be used for personalized treatment of hormonally active malignant tumors in various locations (prostate, breast, etc.).